BioSpace News Archive

A female doctor of mixed race, meets with a senior couple as she reviews recent test results with them. The senior couple of African decent, listens closely as they receive the good news.

Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.

January 5, 2026

·

5 min read

·

BioSpace Insights

Doubtful person, hands on hips, choosing the way as multiple arrows on the road showing a mess of different directions. Choosing the correct pathway, difficult decision concept, confusion symbol.

FDA

Calls for Leadership Stability and Rare Disease Follow-Through at FDA in 2026

After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.

January 5, 2026

·

9 min read

·

Tristan Manalac

Ace Spade Playing Card. Player or Magician Flick and Levitating Poker Card by Hand. Front View. Closeup and Dark Tone

Clinical research

5 Clinical Readouts to Watch in H1 2026

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer’s drug—are poised to reshape therapeutic landscapes.

January 5, 2026

·

7 min read

·

Ben Hargreaves

Bilogical genetic engineering research at laboratory, vector illustration. Doctor conduct experiment with mouse, study dna genes. Scientist near large animal and screen with work analysis.

Opinion

Addressing the Regulatory Reality of Replacing In Vivo Models in Drug Development

The FDA’s announcement that it will phase out in vivo testing requirements for monoclonal antibodies marks a seismic shift. Here’s how industry can adapt.

January 5, 2026

·

6 min read

·

Xiaoxia Li

Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson

Immunology and inflammation

J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.

January 5, 2026

·

2 min read

·

Nick Paul Taylor

Obesity

Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.

January 5, 2026

·

2 min read

·

Dan Samorodnitsky

AbbVie's office in South San Francisco, California

Lung cancer

AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug

The Illinois-based pharma has committed more than $1 billion in milestones to secure rights to ZG006 and join a who’s who of drugmakers targeting the DLL3 protein.

January 5, 2026

·

2 min read

·

Nick Paul Taylor

New Year 2026 Numbers made with Glowing Sparklers on Dark Background.

Weight Loss

Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

January 5, 2026

·

3 min read

·

Annalee Armstrong

Press Releases

Mesoblast Announces Changes to Board of Directors’ Leadership Roles

January 5, 2026

·

6 min read

Press Releases

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe

January 5, 2026

·

2 min read